Psoriasis is recognized as the most common T cell-mediated inflammatory disease in humans. Genetic linkage to as many as six distinct disease loci has been established but the molecular etiology and genetics remain unknown. To begin to identify psoriasis disease-related genes and construct in vivo pathways of the inflammatory process, a genome-wide expression screen of multiple psoriasis patients was undertaken. A comprehensive list of 159 genes that define psoriasis in molecular terms was generated; numerous genes in this set mapped to six different disease-associated loci. To further interpret the functional role of this gene set in the disease process, a longitudinal pharmacogenomic study was initiated to understand how expression levels of these transcripts are altered following patient treatment with therapeutic agents that antagonize calcineurin or NF-B pathways. Transcript levels for a subset of these 159 genes changed significantly in those patients who responded to therapy and many of the changes preceded clinical improvement. The disease-related gene map provides new insights into the pathogenesis of psoriasis, wound healing and cellular-immune reactions occurring in human skin as well as other T cell-mediated autoimmune diseases. In addition, it provides a set of candidate genes that may serve as novel therapeutic intervention points as well as surrogate and predictive markers of treatment outcome.
INTRODUCTION
Psoriasis is a chronic cutaneous inflammatory disease characterized by hyperplastic regenerative epidermal growth, and infiltration of immune cells, particularly T cells into the dermis and epidermis resulting in the release of proinflammatory molecules. 1 The therapeutic benefit of immunosuppressive drugs, eg, Cyclosporin A, FK506, anti-CD4 antibody and IL-2 diphtheria toxin conjugate supports the hypothesis that activated immune cells, particularly T cells are pathogenic effectors of psoriasis. [2] [3] [4] More recently, treatment of psoriasis patients with the immunomodulatory drug, recombinant human interleukin-11, resulted in a downregulation of type 1 cytokines suggesting a role for Th1-specific cells in disease progression. 5 As a result of these studies, there is broad interest among researchers in using psoriasis as a 'model' inflammatory disease mediated by Type 1 T-cells and many new anti-inflammatory or immune-modulating drugs are now tested for the first time in humans in this disease.
The precise etiology of psoriasis remains elusive, although genetic and cellular factors are being elucidated. 6 In addition to environmental factors, there is a genetic component to the disease. About one-third of patients report a family member with the disease and family studies estimate the risk to first-degree relatives at between 8-23%. There is a 65-70% concordance in monozygotic twins, compared to 15-20% in dizygotic twins (reviewed in Bhalerao and Bowcock 7 ). Several psoriasis susceptibility loci have been mapped: PSORS1 on 6p21.3, PSORS2 on 17q, PSORS3 on 4q, PSORS4 on 1cen-q21, PSORS5 on 3q21 and PSORS6 on 19p13. 7 Despite the identification of disease-associated loci, specific genes that play a causative role in disease progression have yet to be identified. Mutations within coding regions affecting protein function or levels have traditionally been examined for disease-related genes. However, mutations affecting transcriptional regulation or mRNA stability can also play a role in disease initiation or progression. To begin to identify such genes and/or pathways affected at the mRNA transcript level, a genome-wide scan of uninvolved and lesional psoriatic skin as well as inflamed skin from non-psoriasis patients was performed using oligonucleotide arrays containing over 7000 human genes. A large number of differentially regulated genes were identified that distinctly classified psoriasis lesions from other uninvolved skin types. The functional significance of these expression patterns was determined by experimentally manipulating human skin in vivo by inducing a cellular immune response or a wound healing response, as well as through therapeutic treatment of patients with immunosuppressant or immunomodulatory drugs that impact the calcineurin or NF-B pathways. These studies indicate that complex genomic expression patterns in inflammatory disease can be resolved into immune-associated vs reactive cellular components by functional manipulation coupled with genome-wide assessments. Furthermore, differentially regulated gene sets and pathways identified by these studies may play a causative role in disease progression or may be early markers of clinical efficacy.
RESULTS

Patient Demographics and Global Expression Analysis of Uninvolved, Psoriatic and Normal Skin
To identify disease-specific genes that were differentially regulated in psoriatic lesions, 6-mm full thickness punch biopsies were obtained from uninvolved and lesional skin of 24 patients (13 females and 11 males) with moderate to severe chronic plaque psoriasis. For comparison, biopsies from normal skin of non-psoriatic patients were also obtained. Biopsies were bisected with one half going towards histological analysis and one half flash frozen and used for RNA expression analysis. All patients enrolled in the study had chronic psoriasis vulgaris affecting at least 10% of their body surface area as measured by a combination of clinical and histological parameters. 5 On average patients were affected with psoriasis for 24 years (range 4-44 years) while only one patient had disease for less than 10 years. Patients were primarily of Caucasian descent and had a mean age of 41 years (range of 23-63 years).
RNA was prepared from lesional and uninvolved skin from an initial group of eight psoriasis patients and compared to normal skin. Samples were analyzed on oligonucleotide arrays containing approximately 7000 human genes (Unigem collection; National Biotechnology Information, www.nature.com/tpj Bethesda, MD, USA). In all instances throughout these studies, individual patient samples were hybridized to arrays. A global comparison of gene expression identified 1295-1858 genes (19-26% of sampled genome) expressed in uninvolved skin and 1352-2587 genes (19-38% of sampled genome) expressed in lesional skin ( Table 1) . The number of genes expressed in normal skin varied from 1383-2375 (20-22%) indicating no overt differences in expression profiles between normal and disease tissue at this global level.
To determine how similar or dissimilar expression profiles were between lesional and uninvolved skin types and across unrelated individuals, a unsupervised cluster analysis approach was taken. 8 This method, which clusters samples based on a hierarchical correlation coefficient, grouped expression patterns of normal and uninvolved skin together while expression patterns of lesional skin formed a separate cluster ( Figure 1a) . A dendrogram of these relationships illustrates greater inter-patient similarities in expression profiles for like skin types than intra-patient similarities between uninvolved and lesional skin types ( Figure 1a ). An illustrative cluster image analysis identified a group of genes whose expression levels were elevated in lesional skin compared to normal or uninvolved skin (Figure 1a ). This result suggested that significant differences in expression profiles between uninvolved and lesional skin could be observed in a differential comparison of gene expression frequency levels.
Identification of a Psoriasis Disease Gene Classification Set
A differential mRNA expression profile of uninvolved to lesional skin was performed. Comparisons of gene fre- 201  psoriasis  1295  1352  519  202  psoriasis  1428  2059  878  203  psoriasis  1671  1847  416  205  psoriasis  1653  2587  1321  212  psoriasis  1776  1868  543  222  psoriasis  1743  1812  340  301  psoriasis  1858  2027  454  304  psoriasis  1680  1773  349  401  tape strip  1383  1619  309  402  tape strip  1534  1683  62  403  tape strip  1502  1724  283  501  DTH  2187  2336  492  503  DTH  2375  2514  925  504  DTH  1612  2331  782 RNA was prepared from one-half of a 6-mm punch biopsy of uninvolved skin and lesional skin obtained from patients prior to treatment with rhIL-11 or Cyclosporin A or following a DTH or tape-stripping reaction. RNA was hybridized to oligonucleotide arrays containing over 7000 human genes. The number of genes called 'present' on each array is shown. The number of differentially regulated genes between uninvolved and lesional skin is presented under differential expression.
quencies were made between uninvolved and lesional skin from the same individual in a pairwise fashion in order to reduce the possibility of confounding demographic parameters. A large number of differentially regulated transcripts were identified. Expression of 340-1321 genes was found to vary by an average factor of two-fold or greater between lesional and uninvolved skin within individual patients (Table 1) . To give an overall picture of gene expression changes in a variety of skin types, off center diagonal plots of the gene expression measurements from each sample were plotted against all other samples and correlation coefficients were calculated (Figure 1b) . Comparison of lesional to uninvolved skin types from the same individuals indicated a higher degree of unrelatedness (r 2 = 0.87) than comparisons of normal to normal skin (r 2 = 0.96), uninvolved to uninvolved skin (r 2 = 0.94) and lesional to lesional skin types (r 2 = 0.98) between unrelated individuals ( Figure 1b ). Comparison of normal skin to uninvolved psoriasis skin also indicated a high degree of similarity (correlation coefficient 0.95) with only 34 genes differing by two-fold or greater ( Figure 1b) . These results validate the consistency of the profiling method and indicate that uninvolved and normal skin from different individuals is more similar to each other than to lesional tissue.
A large degree of heterogeneity in the number of differen- www.nature.com/tpj tially expressed transcripts between uninvolved and lesional skin was observed across patients (Table 1 ). This finding was somewhat unexpected especially since the disease severity of the affected tissue across patients was relatively homogeneous. A likely explanation for these findings is that global analysis of gene expression using relatively small sample sizes has the potential to identify differentially regulated genes that not only correspond to the disease state but also correspond to demographic differences (age, sex or ethnic origin) as well as environmental exposure differences (diet, antigen exposure, temporal gene expression patterns) within the starting patient populations. To minimize the inclusion of differentially regulated genes unrelated to the disease-state, a statistical approach to the data analysis was taken. Average frequency gene expression values between uninvolved and lesional skin were calculated and a paired t-test was performed. Four hundred and seventy-six genes with transcripts levels statistically different between these two defined groups with a confidence level of 95% or greater were identified. This list was further refined to 159 genes by selecting only those genes whose transcript levels differed on average by two-fold or greater between uninvolved and lesional skin. To further confirm the significance of these findings, we performed 100 random permutations of the 16 samples into two groups. This resulted in only 28-102 genes that were statistically significant between two random groups of eight arrays and only 6-15 genes differed by as much as two-fold or greater between the two groups ( Figure  1c ). Class prediction analysis using supervised classification metrics indicated that this 159 gene set can be used to predict with 100% accuracy expression patterns unique to normal/uninvolved skin vs lesional skin (Figure 1d ). These 159 genes therefore comprise a disease classification set for chronic plaque psoriasis.
Characterization of Psoriasis Classification Genes
The 159 differentially regulated genes were categorized into functional groups. The expression levels of these genes are presented as the fold-change of the frequency levels of lesional over uninvolved skin (Figure 2 ). The heterogeneous nature of the cells within the skin biopsies can result in a dilutional effect of messages from rare cell types. Our experience has indicated that small fold-changes in low frequency genes can actually be quite large changes in rare populations of cells such as lymphocytes. Alternatively, they can represent small changes in high frequency cells such as keratinocytes. Therefore, to facilitate a clearer biological understanding of the gene expression changes in the context of these different cell populations, genes are further color coded according to their frequency levels ( Figure 2) .
Genes involved in functions as diverse as transcriptional regulation, metabolic control, protein processing, intracellular signaling, cell cycle control, lymphocyte regulation and extracellular matrix destruction were identified (Figure 2) . Many of these genes were previously reported to be differentially regulated in psoriasis lesional skin such as psoriasin (S100A7), fatty acid binding protein (FABP5), elafin (SKALP, PI3), retinoic acid binding protein (CRAB2), squamous cell carcinoma antigen (SCCA), beta defensin-2 (DEFB2), keratin 17 (KRT17) and keratin 16 (KRT16). 5, 9, 10, 11 This finding validates our microarray comparison approach (Figure 2 ).
Many genes not previously known as being differentially regulated in psoriatic lesions were also identified. For example, overexpression of S100A12 (calgizarin C, ENRAGE), matrix metalloproteinases (MMP-12) and heparin binding protein 17 (HBP-17) were observed ( Figure 2) . A number of genes such as keratin 2, Apolipoprotein E (APOE), GATA3, RB1, calponin 1 (CNN1), Cystatin 6 (CST6), TIMP-3 and TNXA were downregulated in the psoriatic lesions vs uninvolved skin as indicated by their negative fold-change values ( Figure 2 ). Other genes involved in inflammation and immune regulation such as the IL-4R, CD2, CD24, CD47, STAT-1, IFI27, IFI56, MX1, MnSOD, and SCYA1 (MCP1) were elevated in lesional vs uninvolved tissue ( Figure 2 ).
The oligonucleotide array findings for a number of differentially regulated transcripts were extended to a larger psoriasis patient population using a high throughput quantitative RT-PCR approach. Analysis of 16 additional psoriasis patients confirmed elevation of S100A12, K16, HBP17, IL-4R, CCNF, LAD1, MAPKK3, MMP-12 and DSG3 mRNA levels in lesional skin (data not shown). Lower levels of CST6, TNXA, ID4, TIMP-3, GATA3, and ApoE in lesional skin vs uninvolved skin were also confirmed (data not shown). Comparable fold changes were observed between the RT-PCR approach and the oligo arrays for most genes. Better correlation was observed for genes expressed at high levels in both lesional and uninvolved samples. Somewhat reduced fold changes were observed for genes expressed at lower levels. This was due to the greater sensitivity of the RT-PCR approach that resulted in a more accurate quantitation of gene expression levels in the uninvolved samples.
Since transcript levels are not always correlative with protein levels, immunohistochemical analysis of a number of differentially regulated genes was conducted. Consistent with the elevated mRNA levels, protein levels of KRT16, S100A12 and MMP-12 were elevated in lesional vs uninvolved skin of these patients (data not shown). 
Comparative Expression Profiles with Other Cutaneous Inflammatory Skin Conditions
Psoriasis can be viewed as both a focus of T cell-mediated inflammation and as a local wound-healing reaction. To begin to characterize the role of the differentially regulated psoriasis gene set in the pathophysiology of psoriasis, expression profiles were generated for other cutaneous inflammatory/hyperproliferative conditions whose mechanistic components comprised a subset of the psoriasis phenotype. These conditions included antigen-induced inflammation as occurs in the delayed type hypersensitivity reaction (DTH) and regenerative epidermal hyperplasia induced by tape stripping. The DTH reaction was intended as a surrogate of a T cell-driven cellular immune response in skin while tape stripping was intended to activate regenerative epidermal hyperplasia. From past work it is known that tape-stripping induces K16 expression, keratinocyte hyperplasia and up-regulation of some inflammatory cytokines but inflammation as described here is 'non-specific' in the sense that it is not antigen-driven nor T cell-dependent. 11 To induce a DTH reaction, three volunteers were sensitized with DNCB and 72 h later challenged with a second dose of DNCB. A comparison of a biopsy obtained at the site of the DTH reaction to an uninvolved region identified a large number of genes that were differentially regulated between normal and inflamed skin (Table 1 ). On average, 259 genes differed by two-fold or greater in two out of three volunteers ( Figure 3a ). Likewise biopsies were obtained from normal skin and tape stripped skin from three different subjects. Significant differences in gene expression levels were observed between normal vs irritated skin in the three volunteers (Table 1) . One hundred and sixty-one genes were identified that were differentially regulated on average twofold or greater in two out of three tape-stripped samples ( Figure 3a) .
A comparison of the gene sets obtained from the psoriasis patients, DTH reaction and tape stripping showed some overlap of the mRNA expression profiles (Figure 3a ). Thirteen transcripts including KRT16, S100A2, S100A7, S100A9, PI3 and DEFB2 were found to be differentially regulated in all three inflammatory/hyperproliferative conditions ( Figure  3b ). Expression of 23 transcripts including STAT-1, IL-4R and SCYA2 were differentially regulated in psoriasis and following a DTH reaction (Figure 3c ). mRNA transcript levels of 30 genes including KRT17, KRT2A and HBP17 were differentially regulated in psoriasis and following tape stripping (Figure 3d ). Subtraction of these gene sets from the psoriasis gene set identified 94 transcripts including S100A12 (ENRAGE), RAGE and GATA3 that were differentially regulated only in psoriasis. Finally, 11 differentially expressed mRNA transcripts were in common between DTH and tape stripped samples but did not change between lesional and uninvolved psoriasis samples (data not shown).
Pharmacological Treatment of Patients Identifies Pharmacogenomic Classes of Responding Genes
There is a tacit assumption that changes in gene expression are causally related to disease states. However, changes in mRNA expression levels may also be a consequence of the disease process. We hypothesized that changes in gene expression that precede clinical improvement may play a more causal role in disease progression compared with those genes whose expression changes mirror clinical improvement or do not change despite clinical improvement. To better understand possible functional relationships between differentially regulated genes and disease, lesion biopsy samples were obtained from psoriasis patients before, during, and after pharmacological treatment with therapies previously shown to be effective.
Patients were treated with the experimental immunomodulatory cytokine, rhIL-11, or with the immunosuppressant drug, Cyclosporin A. Interleukin-11 has shown activity in psoriasis patients to improve clinical and histopathological scores and these changes correlate with a reduction over time in the expression levels in the skin of type I cytokines such as IFN-␥ and IL-12p40. 5 In addition, stable and/or overexpression of type II cytokines such as IL-4 and IL-5 were observed in the same lesion biopsies.
5 rhIL-11 has been shown to reduce proinflammatory cytokine production in part through the inhibition of NF-B nuclear translocation in activated macrophages but does not appear to regulate the p38/JNK pathway. 12 Cyclosporin A is an immunosuppressant drug active in psoriasis that also inhibits proinflammatory cytokine mRNA production in psoriatic lesions. 2, 5 Mechanistically Cyclosporin A is distinct from rhIL-11 with inhibitory effects on T cell activation particularly through blockade of the calcineurin/NFAT and p38/JNK signaling pathways. 13, 14 Comparisons of gene expression levels between uninvolved and lesional skin following treatment with rhIL-11 or Cyclosporin A cover a diverse spectrum of pathways of therapeutic intervention for inflammatory and autoimmune diseases.
rhIL-11 was administered subcutaneously to patients at either doses of 2.5 g kg −1 day −1 and 5 g kg −1 day −1 or a single 1 mg or 2 mg dose administered once weekly. Cyclosporin A was administered at a dose of 5 g kg −1 day −1 . 2 Fifteen patients were treated with rhIL-11 and nine patients were treated with Cyclosporin A for 8 weeks. At the end of this treatment period, patients were monitored for an additional 4-week follow-up period. Response rates of these patients were typical of those previously reported. 2, 5 Sixty per cent of rhIL-11-treated and 90% of Cyclosporin Atreated patients were considered to have responded to therapy as defined by changes in several clinical and histopathological criteria. 5 To identify genes whose expression patterns change over the course of drug treatment, comparisons in expression profiles of lesional skin were made between responding and non-responding patients prior to drug treatment and at weeks 1, 4, 8 and 12 following initiation of therapy. Gene chip analysis was initially performed on six rhIL-11-treated (five responding and one non-responding) and three Cyclosporin-treated (two responding and one nonresponding) patients. The expression levels of the 159 genes that were significantly different between lesional and uninvolved skin were monitored over the course of drug treatment in these nine patients.
Self-organizing maps (SOMs) were employed to aid in the identification of pharmacogenomic expression patterns. 15 For this analysis, the level of expression of the lesional skin prior to therapy was normalized to a value of one and the change in expression of the 159 gene set over the course of treatment was calculated relative to this baseline level. Four patterns of gene expression changes were identified in responding patients over the course of drug treatment (Figure 4 ). In contrast, no significant change in expression patterns for this gene set was observed over the course of drug treatment in nonresponding patients. Clusters I, II, and III correspond to genes whose levels of expression were elevated in lesional compared to uninvolved skin. Cluster IV corresponds to genes whose expression levels were lower in lesional compared to uninvolved skin. Of particular note, 27 differentially expressed genes mapped to the six identified psoriatic susceptibility loci (Figure 4) . The transcript levels of the 41 genes in cluster I were found to change on average from 2-8 fold in the rhIL-11-and/or Cyclosporin A-treated responding patients as early as one week following the initiation of drug therapy (Figure 4, cluster I) . Interestingly, these changes in expression levels preceded significant clinical improvement as measured by changes in the average PSI or PASI scores. The average PSI score declined only modestly from 9.0 to 8.7 after 1 week of therapy (Figure 4 ). These changes were not observed in the non-responding patients examined. Twelve genes in this cluster including S100A12, ID4, MTX and HBP17 mapped to five of the six known psoriasis-susceptibility loci with the exception of the PSOR5 loci (Figure 4) .
Cluster II corresponded to 91 genes whose transcript levels returned to those found in uninvolved skin but only at the end of drug therapy and not prior to clinical improvement ( Figure 4 , cluster II). Included in this cluster were 11 genes that mapped to all six psoriatic disease loci. Cluster III included 17 genes whose expression levels did not change over the course of therapy despite clinical improvement in the patients skin lesions (Figure 4, cluster III) . Only one of The Pharmacogenomics Journal these genes, KPNB1, mapped to a known psoriasis locus (PSORS2). Finally, cluster IV contained 10 genes whose transcript levels were lower in lesional compared to uninvolved skin. The transcript levels of these genes increased over the course of drug treatment and approached the levels found in uninvolved skin. Changes in the expression levels of some of these genes such as TNXA, RAGE, ID4 and GATA3 were elevated as early as 1 week following the start of therapy and these changes also preceded clinical improvement (Figure 4 , cluster IV). Both RAGE and TNXA map to the PSORS1 locus and CNN1 maps to the PSORS6 locus. Interestingly, a ligand for the RAGE receptor, S100A12, mapped to the PSORS4 locus at 1q21. Quantitative RT-PCR was used to analyze gene expression changes for the early responding genes in clusters I and IV in a larger patient population. Expression levels of genes for S100A12, KRT16, SCYA2, PRKMK3, CST6, TNXA, CCNF and GATA3 were analyzed in 15 patients treated with rhIL-11 and nine patients treated with Cyclosporin A (Figure 5a -b and data not shown). Consistent with gene chip analysis in the smaller patient population, similar changes in gene expression in response to Cyclosporin A or rhIL-11 were observed as early as 1 week following drug therapy in responding patients but not in nonresponding patients. Changes in gene expression continued to decline over the course of drug treatment. This change in gene expression preceded clinical improvement in these patients. Following discontinuation of drug treatment at week 8, mRNA expression levels for some of these genes such as KRT16, S100A12 and SCYA2 began to rebound at week 12 towards those found in untreated lesions (Figure 5a) . rhIL-11 and Cyclosporin A treatment had differential effects on the transcript levels of 11 genes. Interestingly, many of these differences were observed in genes in cluster IV. For example, only rhIL-11-treatment resulted in significant elevation of GATA3, CRIP1 and TNXA. Cyclosporin A treatment did not significantly modulate the transcript levels of these genes. Alternatively, Cyclosporin A significantly reduced MMP-12, CCNF and HBP17 levels following treatment while rhIL-11 had no significant effect on these transcript levels. These differential effects of rhIL-11 and Cyclosporin A were examined in a larger treatment group using quantitative RT-PCR (Figure 5b ). Nine rhIL-11-treated patients who responded to therapy were compared to eight Cyclosporin A-treated patients who responded to therapy. Elevation of GATA3 and TNXA were observed as early as 1 week following rhIL-11 treatment but these changes were not observed in the Cyclosporin A treated patients ( Figure  5b ). Following termination of rhIL-11 administration these transcripts returned to levels observed prior to treatment and these changes in gene expression preceded a clinical worsening of disease. Inhibition of HBP17 and CCNF (cyclin F) was observed in Cyclosporin A-treated responding patients but was not observed in rhIL-11-treated responders (Figure 5b) . Again, upon termination of Cyclosporin A administration these transcripts returned to levels observed in the lesions prior to treatment. These changes were not www.nature.com/tpj observed in either rhIL-11-or Cyclosporin A-treated nonresponding patients (data not shown).
DISCUSSION
The pathophysiology of psoriasis is complex involving multiple cell types and is characterized by epidermal hyperplasia with differentiation of keratinocytes along a regenerative pathway. 1 The underlying disease mechanism involves an immune response with epidermal and dermal infiltration of activated CD4 and CD8 T cells. 16 We have used a pharmacogenomic mRNA expression analysis approach to identify genes linked to these pathogenic processes and cell types in order to understand better the molecular basis of the disease. A comparison of gene expression profiles from psoriatic lesions and uninvolved skin from multiple patients identified over 159 differentially regulated genes that comprise a predictor set of the disease-state as determined by nearest neighbor analysis. As validation of our experimental approach, most genes previously identified by orthogonal methods as being differentially regulated in psoriasis lesions, such as S100A7 (psoriasin), PI3 (elafin), FABP5, DEFB2 (beta defensin-2), KRT16 and SCCA1, were also identified in the current studies. 5, 9, 10, 11 In addition to these known differentially expressed genes, a large number of genes were identified with no previous link to psoriasis and/or inflammatory conditions. Many of these genes fell into clusters that define a number of clinical and histological components of psoriasis such as hyperkeratosis, metabolic dysfunction and immune deregulaton. For example, altered expression of a number of genes involved in protein synthesis, degradation and metabolism were observed. Members of this functional cluster include a group of genes involved in lipid and sterol metabolism (FABP5, fatty acid binding protein 5; APOE, apolipoprotein E; SQLE, squalene epoxidase; ALDH10, fatty aldehyde dehydrogenase; LDLR, low density lipoprotein receptor). Some of these metabolic enzymes are associated with skin diseases. For example, deficiency in fatty aldehyde dehydrogenase is associated with Sjogren-Larsson syndrome that is characterized by ichthyosis and hyperkeratosis. 17 In addition, the LDLR gene maps to the PSORS5 locus supporting a potential link in deregulated lipid metabolism with disease development. In support of this, engulfment of excess lipid molecules by macrophages can result in the subsequent activation of this cell type resulting in the release of proinflammatory cytokines. 18 Another functional cluster of genes can be associated with the regenerative phenotype and hyperkeratosis observed in psoriatic plaques. Genes in this cluster include KLK7 (stratum corneum chymotryptic enzyme), SCCA2 (squamous cell carcinoma antigen-2), SPRR2A and SPRR1B (small proline-rich proteins), TGM1 (keratinocyte transglutaminase), TGM3 (transglutaminase E3) and multiple keratins (Keratin 16, 17, 2 and 6E), PI3 (elafin) and S100A7 (psoriasin). Many of these genes are components of the stratified squamous epithelium, which are cross-linked by transglutaminases or involved in associated proteolytic processes. Finally, gene sets have also been identified related to an activated immune response and inflammation. Genes in this set include RAGE and the S100 family of RAGE ligands which activate and are activated in part by NF-B. 20 Several interferon inducible genes such as IFI56 and IFI27SEP also fall into this category and are consistent with our previous findings that IFN-␥ and IL-12 are elevated in psoriatic lesions. 5 In addition, reduced levels of the TH2-specific transcription factor, GATA3, and elevated levels of IL-4R and the T cell surface molecule, CD2, as well as molecules involved in leukocyte trafficking such as CD24 and CD47 were observed in this study. GATA3 is a transcription factor, abundantly found in T lymphocytes, that positively regulates CD4 cells to a type-2 phenotype. 21 We have previously identified a relative deficiency of type-2 T cells in psoriatic patients. 22 In addition to supporting and enhancing the known etiol-
The Pharmacogenomics Journal ogy of psoriasis and inflammation in general, the differential gene expression profiles allow for the formation of new hypotheses to further explain the underlying pathology of this multi-genic disease. For example, parallels can be drawn between genes that are differentially expressed in tumor cells as well as in psoriasis lesions such as CTSB (cathepsin B), CST6 (cystatin 6), and HBP17 (heparin binding protein 17). CTSB is a lysosomal cysteine protease that plays a role in antigen processing. In the neoplastic state, CTSB is overexpressed in multiple tumor types and its localization correlates with areas of angiogenesis, inflammation and necrosis. 23 It is thought to play a role in the loss of contact inhibition of tumor cells. Expression of cystatin 6, an antiprotease inhibitor of cathepsin B, is downregulated in tumor samples and this downregulation has been correlated with tumor progression. 24 Overexpression of cathepsin B and downregulation of cystatin 6 in the epidermis of psoriasis patients may contribute to deregulated keratinocyte growth and differentiation. Likewise, HBP17, a heparin-binding protein for basic fibroblast growth factor (bFGF), is overexpressed in squamous cell carcinoma. 25 Ribozyme-specific targeting of HBP17 resulted in the decreased growth and angiogenesis of xenograft tumors in mice. Interestingly, HBP17 is upregulated by p38 MAP kinase and inhibition of p38 results in a loss of HBP17 production, further demonstrating a role for the p38 pathway in the progression of disease. 26 A deregulated p38 MAP kinase pathway in psoriasis in addition to effects on the inflammatory process would result in upregulation of HBP17 in the epidermis, resulting in increased angiogenesis and aberrant keratinocyte growth. Interestingly, despite these similarities, conversion of a psoriatic plaque to squamous cell carcinoma is rare, suggesting the presence of additional tumor suppressor pathways that are not deregulated in the lesions. 27 This hypothesis can be tested with further functional analysis.
Association of Differentially Regulated Genes to Psoriasis-susceptibility Loci
Understanding the multifactorial contribution of an unknown number of genes interacting with each other and with the environment has complicated the identification of individual risk-associated genes in multi-genic diseases in general and in psoriasis in particular. Interestingly, 27 genes in the psoriasis gene set identified in the current studies map to one of the six known psoriasis-susceptibility loci. We and others have hypothesized that deregulated genes that reside in chromosomal disease loci may play a fundamental role in the etiology of the disease. Autosomal or somatic mutations in regions of these 27 genes that affect transcriptional regulation or message stability may contribute to increased risk of developing psoriasis. In addition, some of these genes code for transcription factors whose aberrant expression may serve to deregulate other downstream pathways that further contribute to development of the disease. This may contribute to observed epistatic interactions between different psoriasis disease loci. 28 In addition, environmental factors that impact regulation of these transcription factors may also contribute to disease development and progression. These findings could explain the difficulty in identifying disease alleles in the coding region of candidate genes within psoriasis disease loci. 29 Furthermore, a nonrandom cluster of autoimmune susceptibility loci resides on 6p21 and suggests that the genes identified here may play a role in other autoimmune diseases as well. 30 Expression analysis of other complex inflammatory/ autoimmune diseases will validate this approach. These 27 genes have a variety of cellular functions that support a role for the protein products of these transcripts in the etiology of the disease. For example, ID4, located in the HLA locus on 6p21.3, is a dominant/negative regulator of the basic helix-loop-helix (bHLH) family of transcription factors and serves as a general antagonist of cellular differentiation and proliferation in a variety of cell lineages. 31 Cellular injury results in a downregulation of ID4 leading to a www.nature.com/tpj reduction in apoptosis. 32 Reduction of ID4 expression in the epidermis, through either inherited mutations or following insult, may lead to deregulation of a number of downstream bHLH transcription factors that control keratinocyte growth. Another gene, S100A12 (calgranulin C) located on 1q21, is a soluble ligand for the RAGE receptor which has been implicated in activation of the proinflammatory NF-B pathway. 20 The RAGE gene maps to the PSORS1 locus on 6p21.3. Finally, PRKMK3 is mitogen-activated protein kinase kinase 3 (MKK3), an upstream regulator of p38 MAPK. 33 p38 MAPK is activated by proinflammatory molecules such as TNF-␣ and plays a role in the inflammatory process. Blocking p38 activity results in a reduction in the inflammatory state.
34
Comparison of the Psoriasis Gene Set to Other Cutaneous Inflammatory Conditions
A comparison of the 159 gene set to expression profiles from inflamed skin following a DTH response or tape stripping has allowed us to construct genomic maps that resolve psoriasis into immune-associated vs reactive cellular components. Some of the genes that comprise these maps are psoriasis-specific while others are shared in common with general skin inflammatory conditions. Furthermore, some of these genes are only found differentially regulated in either DTH or tape-stripped samples but not both. Functional characterization of the genes shared and/or specific to these experimental conditions was consistent with the known biology of the systems. For example, many of the differentially regulated transcripts shared between psoriasis and DTH samples are immune-specific genes expressed in various cell types of the immune system such as monocytes, B cells and T cells or are induced by proinflammatory immunomodulatory cytokines such as IL-12 or IFN-␥. Genes shared between psoriasis and tape stripped samples are expressed predominantly in cells of epithelial origin, such as keratinocytes, consistent with the shared wound healing component of both tissue types. Psoriasis-specific genes crossed the spectrum of cell types such as neutrophils, leukocytes and keratinocytes. These genes also crossed the spectrum of cellular functions from roles in metabolism (ATP1AL1, HAL), transcriptional regulation (ID1, ID4), immune modulation and inflammation (S100A12, IFI56) and cornified envelope development and keratinocyte growth regulation (TGM1, GJB2, SPRR2A).
Genes activated in an antigen-specific manner during a DTH response may play a role in a variety of inflammatory conditions such as rheumatoid arthritis and Crohn's disease while genes activated during a tape-strip reaction may play a more fundamental role in generalized wounding of the skin. In support of this, a differentially regulated gene identified in the current studies as overexpressed during the DTH response, MMP-12, has previously been shown through microarray analysis to be deregulated in Crohn's and RA tissue. 35 Other genes overexpressed in tape-stripped samples, such as HBP17, have been shown to play a role in angiogenesis and wound healing.
Pharmacogenomic Profiling Identifies Disease Gene Candidates and Novel Pathways for Pharmacological Intervention
Changes in gene expression can be causally related to the disease state or may be a consequence of the disease process. A general problem with genome-wide differential expression analysis is the difficulty in differentiating between these two possibilities. For example, the gene DEFB2, a defensin, is an antimicrobial protein induced during inflammation whose expression levels are increased as much as 200 fold in psoriatic lesions.
36 DEFB2 may be upregulated as an effect of the wound healing process. However, recent studies indicate that defensins are also chemoattractive for lymphocytes and may contribute to adaptive immunity by mobilizing T cells and dendritic cells. 37 Thus, descriptions of the biological role of these differentially expressed genes are not sufficient to determine candidates for further functional analysis. This is particularly the case when the differentially expressed gene is relatively uncharacterized. To address this issue in an in vivo human setting, we analyzed psoriasis biopsy tissue from patients following pharmacological intervention.
Drugs such as rhIL-11 and Cyclosporin A are known to block the NF-B and calcineurin/p38 pathways, respectively. We have hypothesized that changes in gene expression that precede clinical improvement may play a more causal role in disease progression as opposed to genes whose expression changes mirror clinical improvement or do not change despite clinical improvement. This approach identified a subset of 41 differentially regulated genes that returned to normal or uninvolved levels following therapeutic intervention with rhIL-11 or Cyclosporin A at time points that preceded clinical improvement. Members of this group included 12 genes such as ID4, HBP-17, KRT16, S100A2, S100A9, S100A12, GNA15, MTX, PRKMK3, and SCYA2 that all localized to psoriasis susceptibility loci. Sequence analysis of these genes in families with a history of psoriasis may help to identify specific affected alleles at susceptibility loci.
Pharmacogenomic analysis also can serve to identify pathways suitable for pharmacological intervention. Of particular interest is the finding that 11 IFN-␥-regulated genes are aberrantly expressed in psoriasis lesions. Thus, agents that target the IFN-␥ or Type I cytokine pathway may have future therapeutic potential. For example, neutralization of the IFN-␥ inducer, IL-12, or inhibition of IL-12 production from mature Langerhans cells may provide effective treatment. In addition, blockade of Type I cytokine production from activated CD8 + Tc1 cells or CD4 + Th1 cells may also be effective. This approach has also allowed us to begin to identify in vivo pathways that are modified in a drug-specific manner. For example, 11 genes were differentially regulated between rhIL-11-and Cyclosporin A-treated patients. Blockade of the NF-B pathway by rhIL-11 resulted in specific upregulation of a number of genes including the type II helper T cell transcriptional regulator GATA3 and the lymphocyte differentiation and maturation molecule CRIP1. Also, rhIL-11 upregulates the extracellular matrix protein, TNXA. TNXA deficiency has been associated with Ehlers-Danlos syndrome that is characterized by skin hyperextensibility, vas-
The Pharmacogenomics Journal cular fragility and poor wound healing. 38 Cyclosporin A does not impact the expression of these transcript levels; rather it specifically upregulates transcript levels for several genes such as CCNF and HBP17. Induction of HBP17 is regulated by the p38/JNK pathway that is blocked by Cyclosporin A. 39 Understanding the impact of different therapeutic treatments on these pathways may help differentiate between desirable (specific and efficacious) and undesirable (toxic) drug activities.
These studies present for the first time a genome-wide expression response to pharmacological intervention in a longitudinal study and indicate that this method has utility in prioritizing disease-associated genes for further functional genomic analysis. Pharmacogenomic gene expression analysis of a complex multi-genic disease such as psoriasis has the potential to identify novel regulators of the disease-state. One hundred and fifty-nine genes were identified that are differentially expressed in the disease state. Of these, 41 transcripts are modulated rapidly by inhibitors of the calcineurin and NF-B pathways and 12 of these genes map to known psoriasis susceptibility loci. Further analysis of these genes will aid in elucidating the etiology of psoriasis and perhaps other inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and Crohn's disease where NF-B and Type I cytokines also play a predominant role. They may also serve to identify novel therapeutic intervention points or clinical markers of drug efficacy.
METHODS
Study Design and Psoriasis Patient Entry Criteria
These studies were approved by The Rockefeller University Hospital Institutional Review Board, New York, NY. Thirty adult patients (16 female, 14 male) with chronic psoriasis vulgaris affecting at least 10% of their body surface area, as measured by a combination of clinical and histological parameters as previously described, signed informed consent forms and were enrolled in this study. 5 Patients had stable chronic disease as evidenced by a median duration of disease of 24 years (range 4-44 years). Patients were primarily of Caucasian descent with a mean age of 41 years (range of 23-63 years).
Global clinical assessment of each patient before, during and after therapy was based on the Psoriasis Area and Severity Index (PASI) as described previously. 2 The grading system used to measure local clinical disease activity was the Psoriasis Severity Index (PSI). The PSI index grades individual psoriasis lesions for scale, erythema, and induration on a 0-6 point scale for each parameter (0, absent; 1, trace; 2, mild; 3, mild to moderate; 4, moderate; 5, moderate to severe; and 6, severe). The final score sums the individual parameters for a range of 0-18. 40 Patients were treated on an outpatient basis with rhIL-11 (n = 21) or Cyclosporin A (n = 9) for 8 weeks. The dose and schedule selection of rhIL-11 (2.5 g kg −1 day −1 , 5 g kg
day −1 , and 1 mg once weekly and 2 mg once weekly) and Cyclosporin A (5 g kg −1 day −1 ) was as previously described. 5 At the start of enrollment, a psoriatic plaque was chosen for weekly assessment of lesion severity scores by the study coordinator. A 6-mm punch biopsy was taken of this lesional skin prior to rhIL-11 or Cyclosporin A treatment and at weeks 1, 4, 8 and 12 during rhIL-11 or Cyclosporin A treatment. In addition, prior to initiation of treatment, a 6 mm punch biopsy was taken from uninvolved skin at a location of the patient's choosing. Biopsies were equally divided for immunohistochemical analysis and for RNA preparation. Normal skin was obtained from healthy volunteers. Six-micrometer cryostat sections were made from frozen biopsies, were reacted with antibodies to CD3, CD8, keratin 16, Ki67, ICAM-1, or HLA-DR and processed for immunohistochemistry as previously described. 5 Computer-assisted image analysis was used to quantify epidermal thickness and the number of CD3+, CD8+, or Ki67+ cells in tissue sections as described.
5
DTH and Tapestrip Induction
Patients were sensitized with 2 mg of dinitrochlorobenzene (DNCB, 0.2 ml of 1% solution) to an area of normal skin. The DNCB was placed into a 2-cm hole in a Teflon template and slowly evaporated under a steady stream of nitrogen gas. The area was covered with a sterile bandage. Patients returned in 2 weeks for challenge with 50 g DNCB (0.1 ml of 0.05% solution) in the same fashion as described above. If no reaction occurred within 96 h, a second challenge was placed with 100 g (0.2 ml of 0.05% solution). A 6-mm full thickness punch biopsy was taken from the middle of the erythematous plaque (DTH-reaction) for histological and RNA preparation 72 h following challenge. For tape stripping, a 1 × 3 inch area of normal skin was repetitively stripped with adhesive tape as previously described. 11 When a smooth glistening erythematous epidermis was reached, the stripping was stopped; the wound was covered with a sterile bandage. After 24 h, a full thickness 6 mm punch biopsy was taken for histological and RNA preparation.
Isolation of RNA and Preparation of Labeled Microarray Targets
Total RNA was isolated from one-half of a 6-mm full thickness skin biopsy using the RNeasy mini kit (Qiagen, Valencia, CA, USA). Labeled target for oligonucleotide arrays was prepared using a modification of the procedure described by Lockhart et al. 41 Two micrograms total RNA were converted to cDNA by priming with an oligo-dT primer containing a T7 DNA polymerase promoter at the 5Ј end. The cDNA was used as the template for in vitro transcription using a T7 DNA polymerase kit (Ambion, Woodlands, TX, USA) and biotinylated CTP and UTP (Enzo, Farmingdale, NY, USA). Labeled cRNA was fragmented in 40 mM Tris-acetate pH 8.0, 100 mM KOAc, 30 mM MgOAc for 35 min at 94°C in a final volume of 40 l.
Hybridization to Affymetrix Microarrays and Detection of Fluorescence
Ten micrograms of labeled target were diluted in 1 × MES buffer with 100 g ml −1 herring sperm DNA and 50 g ml
acetylated BSA. To normalize arrays to each other and to estimate the sensitivity of the oligonucleotide arrays, we www.nature.com/tpj included in vitro synthesized transcripts of 11 bacterial genes in each hybridization reaction as described by Hill et al. 42 The abundance of these transcripts ranged from 1:300 000 (3 ppm) to 1:1000 (1000 ppm) stated in terms of the number of control transcripts per total transcripts. As determined by the signal response from these control transcripts, the sensitivity of detection of the arrays ranged between ෂ1:300 000 and 1:100 000 copies per million. Labeled probes were denatured at 99°C for 5 min and then 45°C for 5 min and hybridized to oligonucleotide arrays comprised of over 7000 human genes (HuGeneFL, Affymetrix, Santa Clara, CA, USA). Arrays were hybridized for 16 h at 45°C with rotation at 60 rpm. After hybridization, probes were removed and the cartridges washed extensively with 6 × SSPET and stained with phycoerythrin coupled to streptavidin as described.
41
Gene Expression Data Reduction
Data analysis was performed on raw fluorescent intensity values using GENECHIP 3.2 software (Affymetrix). GeneChip 3.2 software uses an algorithm to calculate the likelihood as to whether a gene is 'absent' or 'present' as well as a specific hybridization intensity value or 'average difference' for each transcript represented on the array. The algorithms used in these calculations are described in the Affymetrix GeneChip Analysis Suite User Guide (Affymetrix). The 'average difference' for each transcript was normalized to 'frequency' values according to the procedures of Hill et al. 42 This was accomplished by referring the average difference values on each chip to a calibration curve constructed from the average difference values for the 11 control transcripts with known abundance that were spiked into each hybridization solution. This process also served to normalize between arrays. 42 Specific transcripts were evaluated further if they met the following criteria. First, genes that were designated 'absent' by the GENECHIP 3.2 software in all samples were excluded from the analysis; 3320 (49%) of the transcripts met this criteria. Second, in comparisons of transcript levels between arrays, a gene was required to be present in at least 50% of the arrays comprising one or more groups. Third, for comparisons of transcript levels between groups, a t-test was applied to identify a subset of transcripts that had a significant (P Ͻ 0.05) difference in frequency values. Fourth, average fold changes in frequency values across this statistically significant subset of genes was required to be 2-fold or greater. These criteria were established based on numerous replicate experiments performed in our lab that estimated the intra-assay reproducibility (data not shown). Quantitative RT-PCR was also performed on a select subset of genes to further validate these criteria (data not shown).
Quantitative Reverse Transcriptase-polymerase Chain Reaction (RT-PCR)
Quantitative RT-PCR was performed as previously described. 5 RNA samples from patient biopsies were treated with 10 U of RQ1 DNase I (Promega, Madison, WI, USA) for 30 min at 37°C. rTth DNA polymerase was used to reverse transcribe and amplify 10 ng of total RNA in a single tube assay using the TaqMan EZ RT-PCR kit (ABI, Foster City, CA, USA) with gene specific sense and anti-sense primers and a probe fluorescently labeled at the 5Ј end with 6-carboxyfluorescein (6-FAM). Amplification was performed using the ABI Prism 7700 sequence detection system as described by the manufacturer (ABI). Primers and fluorescently labeled probes were generated using Primer Express software (ABI). Sequence-specific amplification was detected as an increased fluorescent signal of 6-FAM during the amplification cycle. Quantitation of gene-specific message levels was based on a comparison of the fluorescent intensity in the unknown mRNA sample to the fluorescent intensity from a standard curve of known mRNA levels. Amplification of the gene for human acidic ribosomal protein (HARP) was performed on all samples tested to control for variations in RNA amounts. 43 All genes were subsequently normalized to HARP mRNA levels. Levels of gene-specific messages were graphed as normalized message units as determined from the standard curve. A no template control was included in each amplification reaction to control for contaminating templates.
Statistical Analysis
Quantitative measures of gene expression changes between groups were statistically evaluated using the JMP 3.2.6 statistical discovery software package (SAS Institute, Cary, NC, USA). Unsupervised hierarchical clustering of samples into groups on the basis of similarity of their expression profiles was performed using the procedure of Eisen et al. 8 Self organizing maps (SOM) were constructed using methods described by Tamayo et al. 15 Nearest neighbor prediction analysis and supervised cluster analysis was performed using metrics defined by Golub et al. 44 The Pearson correlation coefficient was chosen to measure the degree of overall similarity between expression profiles. For hierarchical clustering, SOM analysis, and nearest neighbor prediction analysis, data were log transformed and normalized to have a mean value of zero and a variance of one. Differences between paired sites were analyzed using 2-tailed paired ttest. An unpaired t-test was used to compare normal to uninvolved skin. In all comparisons a P value Ͻ0.05 was used to indicate statistical significance.
Note Added in Proof
Since submission of this manuscript for publication, Bowcock et al have also described differential expression profile analysis of psoriasis lesions (Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, Catier J, Fernandez-Vina MA and Merter A. Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001; 10: 1793-1805.
